Telmisartan
48 NDCs across 13 manufacturers|46 Generic,2 Brand
Telmisartan is used to treat diabetic nephropathies, heart failure, hypertension and left ventricular dysfunction, per the National Library of Medicine's MED-RT classification.
▸ More about this market▾ Less
The brand product was first FDA-approved on Nov 10, 1998, and the first generic was approved Jan 8, 2014. FDA's Orange Book lists 45 AB-rated (therapeutically equivalent) products for this ingredient. In 2024, Medicare Part D spent $39 million on Telmisartan across 1.3 million claims for 337,000 beneficiaries.
Telmisartan is available as 48 NDCs from 13 manufacturers (46 generic, 2 brand), with NADAC prices from $0.11 to $4.50 per EA — the most expensive product costs about 43× the cheapest. Every pack size and labeler in this drug market is compared side-by-side below.
Total NDCs
48
46G / 2B
Manufacturers
13
competing in market
Price Spread
$0.11 – $4.50
per EA
7d Activity
avg +1.5% WoW · of 48 NDCs
Market Price Trend
Monthly average NADAC per unit, split by generic and brand.
Explore this market from other angles
Move from the molecule page into the supplier, class, and trend views that create the strongest internal-link cluster for this market.
Top supplier
Glenmark Pharmaceuticals Inc., USA manufacturer profile
Open the supplier page for the manufacturer with the strongest footprint in this market.
Lead class
Angiotensin 2 Receptor Blocker class view
See how this market rolls up into the broader therapeutic class and compare other drugs in the same bucket.
Trend hub
Latest market trends
Move from this single molecule into the current cross-market mover and volatility view.
Guide
How to interpret NADAC
Review the benchmark methodology behind the prices and spreads shown on this market page.
Manufacturer Breakdown
13 manufacturers producing TELMISARTAN(4 pricing outliers)
Frequently Asked Questions
What is Telmisartan used to treat?
Telmisartan is used to treat diabetic nephropathies, heart failure, hypertension and left ventricular dysfunction, per the National Library of Medicine's MED-RT classification.
When did Telmisartan become available as a generic?
FDA approved the first generic Telmisartan (ANDA) on Jan 8, 2014. The Orange Book currently lists 45 AB-rated products for this ingredient, meaning FDA considers them therapeutically equivalent to the brand.
How much does Medicare spend on Telmisartan?
In 2024, Medicare Part D spent $39 million on Telmisartan across 1.3 million claims for 337,000 beneficiaries.
How many Telmisartan products are on the market?
The Telmisartan drug market contains 48 NDCs from 13 manufacturers — 46 generic and 2 brand products.
What is the price range for Telmisartan?
NADAC reference prices for Telmisartan range from $0.1058 to $4.5019 per EA — the most expensive product costs about 43× the cheapest.
Is generic Telmisartan cheaper than brand?
The average generic NADAC for Telmisartan is $0.1472 per EA, versus $4.4921 for brand-labeled products — brand versions average about 31× the generic price.
Which manufacturers make Telmisartan?
13 manufacturers list Telmisartan in NADAC. Ranked by number of NDCs, the largest are Glenmark Pharmaceuticals Inc., USA (9), Aurobindo Pharma Limited (6), Mylan Pharmaceuticals Inc. (6), Jubilant Cadista Pharmaceuticals Inc. (3), Micro Labs Limited (3).
How has the price of Telmisartan changed recently?
Over the past 7 days, 29 Telmisartan NDCs rose and 14 fell, with a market-wide average change of +1.5%.